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A workshop on alternative toxicological testing methodologies was convened by the Scientific
Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC) 26-31 January
1997 in Ispra, Italy, at the European Centre for the Validation of Alternative Methods.The purpose
of the workshop was to assess the current status of alternative testing methodologies available
to evaluate adverse human health and environmental effects of chemicals. Another objective of
the workshop was to identify and recommend research needed to fill knowledge gaps that would
lead to new test methodologies. Four work groups were established to address conceptual
issues, acute toxicity, organ toxicity, and ecotoxicology. Ajoint workshop report was prepared for
each topic and included recommendations for the development and use of alternative methods.
Participants concluded that alternative methods and approaches are available that can be
incorporated into tiered strategies for toxicological assessments. Use of these methods will
reduce the numbers of animals required, and in some instances reduce animal pain and distress.
It was recommended that future efforts to develop test methods should emphasize mechanism-
based methods that can provide improved predictions of toxicity. Continued international
cooperation was encouraged to facilitate future progress in the development of alternative
toxicological testing methods. These methods will provide for improvements in human health
protection, environmental protection, and animal welfare. Environ Health Perspect 106(Suppl
2):405-412 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-2/405-412stokes/abstract.html
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Background
The Scientific Group on Methodologies chemicals into the environment. To assess
for the Safety Evaluation of Chemicals the current status of alternative testing
(SGOMSEC) is an international organiza- methodologies available to evaluate such
tion whose objective is to contribute to the risks, a SGOMSEC workshop was orga-
reduction and prevention ofhuman health nized and convened 26-31 January 1997,
and environmental risks caused by the in Ispra, Italy, at the European Centre for
introduction of natural and man-made the Validation ofAlternative Methods.
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Knowledgeable scientists from the interna-
tional community were invited to partici-
pate and prepare comprehensive review
papers on specific topics for discussion at
theworkshop.
Theworkshop focused on newor revised
testing methods forwhich there are planned,
ongoing, or completed validation studies,
and thosewhich will likely be considered for
regulatory use. An additional objective ofthe
workshop was to identify and recommend
research needed to fill knowledge gaps that
wouldlead to newtest methodologies.
Workshop participants were assigned to
four work groups: conceptual issues, acute
toxicity, organ toxicity, and ecotoxicology.
Each group prepared a joint report on the
status ofalternative test methods and issues
relevant to their topic, as well as recom-
mendations for their future development
and use. The workshop report, published
in this Environmental Health Perspectives
Supplement, consists of this overview, four
joint reports, and background papers
prepared byworkshop participants.
The purposes ofthis workshop overview
is to provide an introduction about alterna-
tive testing methods, and to summarize the
conclusions and recommendations of the
four joint reports (1-4). Additional details
about specific issues and methods can be
found in the joint work group reports and
the individual reviewpapers.
Introduction
It is estimated thatover 80,000 chemicals are
currendy in use and that an average of2000
new ones are introduced annually (5). The
public and the environment maybe exposed
to these chemicals during their manufacture,
distribution, use, anddisposal. Chemicals are
present in pharmaceuticals, foods, personal
careproducts, pesticides, industrial solutions,
anddeaningagents, andexposure mayoccur
in the home and workplace. Exposure may
also occur from chemicals in the environ-
ment as pollutants in water, air, or soil. To
safeguard human health and the envi-
ronment, governments adopt toxicological
testing methods to evaluate the potential
hazardous effects ofchemicals or to demon-
strate the safety ofsuch chemicals. These test
methods generate information used for
premarket evaluation of new products,
hazard classification, and risk assessment.
Depending upon testing outcomes, industry
and regulatory agencies may implement pre-
vention and risk management practices to
protectpublichealth and the environment.
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The potential adverse effects ofchemicals
are currently assessed largely by tests involv-
ing laboratory animals. However, several
factors have influenced the scientific com-
munity to develop newalternative test meth-
ods. One major factor influencing the
development of new test methods is the
enormous advances in the understanding of
molecular and cellular mechanisms of tox-
icity. These advances have been matched by
technological advances in tissue culture,
genetic engineering of cells and whole ani-
mals, and high throughput automated
testing equipment. Much ofthis newknowl-
edge and technology is being incorporated
into alternative testingmethodologies.
Another factor affecting the development
of new test methods is the desire for tests
that will be more predictive of potential
chemical toxicity and thereby support
improved riskassessment. There is also great
interest on the part ofboth government and
industry to develop tests that are more cost
and time efficient. For instance, the current
rodent bioassay for assessing carcinogenicity
costs $1 million to 3 million and requires at
least 3 years to complete. More efficient
testing methods may reduce the time
required to bring new products to the mar-
ketplace and increase the amount of useful
information that can be obtained.
New test method development is also
being stimulated by public concern about
the use ofanimals for testing. This concern
has resulted in legislative mandates in the
United States and Europe to develop alter-
native test methods. In 1986 laws were
enacted in the United States that required
consideration ofalternatives prior to the use
of animals in research, testing, or educa-
tion. A component of the U.S. National
Toxicology Program, the National Institute
of Environmental Health Sciences, was
directed by a 1993 law to develop and vali-
date alternative methods that can reduce or
eliminate the use of animals in acute or
chronic safety testing (6). The institute was
also directed to develop criteria and
processes for the validation and acceptance
of test methods by regulatory agencies. In
1986 the European Union (EU) issued a
directive that states that an animal proce-
dure shall not be performed if nonanimal
procedures are reasonably and practically
available (7). A 1993 EU directive would
have prohibited the testing ofcosmetics in
animals as ofJanuary 1998, ifscientifically
validated nonanimal alternative methods
were available (8).
Alternative test methods are generally
regarded as those that incorporate some
aspect ofreplacement, reduction, or refine-
ment of animal use. These include meth-
ods that use nonanimal systems or lower
species to partially or fully replace higher
animals, methods that reduce the number
of animals required, and methods that
refine animal use by lessening or eliminat-
ing pain or distress and enhancing animal
well-being. Virtually every new testing
method incorporates some aspect ofrefine-
ment, reduction, or replacement compared
to the corresponding traditional test. Thus
in this report, alternative methods and new
methods will be used interchangeably.
Alternative Methodologies
and Conceptual Issues
This work group addressed broad issues
associated with the application and use
of alternative testing methods for risk
assessment (1). New testing models and
approaches are available that can provide
considerable information about chemical
toxicity. Examples presented include genet-
ically engineered animal models, quantita-
tive structure-activity relationship (QSAR)
models, and physiologically based bioki-
netic (PBBK) models. Considerations for
integrating new test methods into testing
strategies were also discussed.
RiskAssessment
The risk assessment process evaluates
potential adverse health effects that may
arise from exposure to a chemical. This
assessment includes a qualitative judgment
ofthe potential for the chemical to produce
adverse effects, and a quantitative judgment
ofthe influence ofdose on the potential for
adverse effects. Alternative test methods
may recapitulate the initial toxic event,
referred to as the mechanism oftoxicity, or
they may recapitulate one or more subse-
quent events leading to injury or disease,
referred to as the mode ofaction. Improved
understanding of toxic mechanisms and
modes ofaction will influence the type and
amount of data considered most useful for
determining potential toxicity. Additional
alternative methods likely will be needed to
generate this data.
MehanisticApproaches
Mechanistic test methods are based on an
understanding ofthe biologic events respon-
sible for, or associated with, the effect
observed. These tests provide information
concerning the molecular, cellular, or physi-
ological mechanisms by which substances
exert their effects on living cells and organ-
isms. They are contrasted to correlative test
methods, which are based on statistical
relationships of phenomena that cannot
be explained on a mechanistic basis.
Correlative tests are unlikelyto lead towide-
spread acceptance, and itwas recommended
that future efforts should be directed at the
development of mechanistic test methods.
There was also consensus that develop-
ment of relevant and reliable mechanistic
tests is highly dependent on progress in the
fundamental science oftoxicology.
MolecularBiology
Molecular biology techniques are being
used to develop new animal models for
toxicity testing. These models include
transgenic and "knockout" animals that
have genetic material introduced or
deleted, respectively, to generate models
that have greater sensitivity and specificity
for the toxic end point of interest.
Currently, product development and
public health decisions on carcinogenic-
ity depend on the expensive and time-
consuming chronic 2-year rodent bioassay.
However, rodent models have been created
in which critical genes serve as specific tar-
gets for potential chemical carcinogens.
Examples include three models being
evaluated in an international multilabora-
tory effort: the p53 tumor-suppressor gene
deficient mouse, the Tg.AC mouse that
carries an activated ras oncogene, and the
ras HII mouse which carries a human ras
oncogene. Ongoing and planned studies
on these test models will provide informa-
tion on their potential usefulness for risk
assessment purposes.
ComputerAlgorithms
Computer-based analysis ofdiverse chemical
properties is being used to create algo-
rithms for predicting toxicological effects
ofstructurally related chemicals. An exam-
ple is the use ofQSAR models, which have
been extensively developed and used. This
model is based on the premise that the bio-
logic properties of a chemical are inher-
ently linked to its molecular structure.
QSAR models are currently being incorpo-
rated in the initial stages of tiered testing
approaches to estimate the likelihood of a
toxic effect. Information is used to deter-
mine candidates for additional toxicity
testing or furtherproduct development.
Exposure-EflfectRelationships
Determination ofthe absorption, distribu-
tion, metabolism, and excretion ofchemi-
cals is necessary to fully characterize their
potential toxicity. This information can be
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used to create PBBK models that predict
target organ concentrations and toxicity for
specified external doses. In PBBK model-
ing, physiological and chemical-specific
parameters are combined to predict tissue
concentrations. The model integrates data
from in vivo and in vitro testing methods
with data from the target species, such as
human blood levels from exposed popula-
tions. PBBK modeling is also useful for
selecting the most appropriate test models
and for estimating chemical doses for in
vitro and in vivo testing.
Integration intoTestingStrategies
The development of an ever-increasing
number of new test methods is likely to
continue. The usefulness ofthese methods
must be carefully assessed and the methods
integrated into logical, stepwise testing
strategies that provide reliable and relevant
information. Care must be taken to avoid
the adoption of methods that do not pro-
vide meaningful information useful for
decision-making. An approach for integrat-
ing new test methods for carcinogenicity
testing is discussed in the joint report by
Blaauboer et al. (1).
ValidationandAcceptance
Requirements for the use of alternative
testing methods are validation and accep-
tance. Validation is the process ofestablish-
ing the reliability and the relevance ofa test
method. Reliability is the reproducibility of
results within and between laboratories, and
relevance is the extent to which a test is
meaningful and useful for a particular pur-
pose. Acceptance occurs when the test
method is considered suitable for risk assess-
ment purposes aimed at the protection of
human health or the environment. New test
methods evolve through a series of steps
from development ofthe method to valida-
tion and finally acceptance. Validation of a
new test method in accordance with estab-
lished criteria is a prerequisite for regulatory
acceptance (9). Furthermore, separate crite-
ria must be met to achieve regulatory accep-
tance (9). Specific validation and regulatory
acceptance criteria were developed at an
Organisation for Economic Cooperation
and Development (OECD) international
workshop in 1996 (9) and have been
described in another recent report on this
subject (10).
Validation Criteria
The following criteria (9) should be met for
validation of new animal or nonanimal
methods:
* Arationale for the test method should be
available, induding a clear statement of
scientific need andregulatorypurpose.
* The relationship of the end point(s)
determined by the test method to the
in vivo biological effect and to the toxi-
city of interest must be addressed and
limitations of the method must be
described.
* A formal detailed protocol must be
provided and should be readily avail-
able in the public domain. It should be
sufficiently detailed to enable replica-
tion by other users and should include
data analysis and decision criteria. Test
methods and results should be avail-
able, preferably in a peer-reviewed
publication; and test results should
have been subjected to independent
scientific review.
* Intratest variability, repeatability, and
reproducibility of the test method
within and among laboratories should
have been demonstrated. Data should
be provided describing the level of
intra- and interlaboratory variability
and howthesevarywith time.
* The performance of the test method
must have been demonstrated using a
series ofreference chemicals, preferably
coded to exclude bias.
* The performance of the test method
should have been evaluated in relation
to existing relevant toxicity data and
information from the relevant target
species.
* All data supporting the assessment of
the validity ofthe test method, includ-
ing the full dataset collected in the vali-
dation study, must be available for
review.
* Normally, these data should have been
obtained in accordance with OECD
principles ofGood Laboratory Practice.
AcceptanceCriteria
The following criteria (9) should be met
before new tests are accepted by regulatory
agencies:
* Application of the method provides
data that adequately predict the end
point of interest in that the data
demonstrate a linkage between either
the new test and an existing test
method, or the new test and effects in
the target species.
* Use of the method generates data for
risk assessment purposes that are at
least as useful as, and preferably better
than, those obtained using existing
methods. This will give a comparable
or better level of protection for human
health or the environment.
* Adequate testing data for chemicals and
products representative of the type of
chemicals administered by the regula-
tory program or agency (e.g., pesticides,
cosmetics) are provided
* The test must be robust and transferable
and allow for standardization. If highly
specialized equipment, materials, or
expertise are required, efforts should be
sought to facilitate transferability. This is
an important criterion to be considered
at an earlystage ofavalidationstudy.
* The test is cost effective and likely to be
used.
* Justification (scientific, ethical, eco-
nomic) should be provided for the new
method with respect to any existing
methods available. In this respect due
consideration should be given to ani-
mal welfare, including the 3Rs (refine-
ment, reduction, and replacement of
animal use).
Recommendations
The following are recommendations from
the SGOMSEC workshop (1) for the future
development and useofalternativemethods.
* The rate of development of alternative
tests for use in toxicological assessments
should be increased.
* Increased emphasis should be placed on
the development of mechanism-based
methods for specific aspects oftoxicity.
* Investment in the development offun-
damental research that underpins toxi-
cology and toxicity testing should be
increased.
* Training institutions, granting bodies,
and regulatory agencies should be
encouraged to support research and
training that will enhance the develop-
ment and use ofalternative systems.
* Accepted alternative methods should be
integrated into toxicity assessment of
chemicals.
* International cooperation in develop-
ment, validation, and acceptance ofalter-
native methodsshouldbeencouraged.
* In the interest of the most effective
development and use of alternative
methods, international harmonization
of chemical toxicity classification
schemes should beencouraged.
Alternative Testing
Methodologies for
AcuteToxicity
Acute toxicity testing determines the poten-
tial for injury or death from intentional or
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accidental single or short-term chemical
exposure. This information is needed to
properly classify and label potential haz-
ards. Acute toxicity testing data are also
used to determine the appropriate protec-
tive equipment or procedures needed to
prevent human exposure and subsequent
injury or death. Three important end
points for acute toxicity were addressed at
the workshop (2): ocular toxicity, dermal
toxicity, and acute systemic toxicity. In
addition, the validation process and algo-
rithms for interpretation of data from in
vitromethods were addressed.
GeneralTestingStrategy
The incorporation of alternative methods
into tiered testing approaches has resulted in
the reduction, and to some extent, refine-
ment of animal use. This tiered approach
involves a decision after each level oftesting
as to whether there is sufficient information
for hazard classification, or whether addi-
tional testing is necessary. The process
begins with information about a chemical's
properties, a review of the scientific litera-
ture, and QSAR assessment. Subsequent
stages of testing may involve in vitro tests,
laboratory animals, or humans. Human vol-
unteers are used onlywhen ethically feasible
and after approval byan ethical review com-
mittee. The extent of testing at each stage
and the decisions reached will depend on
the test outcome and the usefulness of the
test forpredicting toxicity orlackoftoxicity.
There are currently no scientifically ade-
quate methods that can totally replace ani-
mals for acute toxicity testing. However,
alternative methods are available that can
and should be incorporated into tiered test-
ing strategies to reduce the number of ani-
mals needed and to reduce the severity of
potential pain and distress.
OcularToxicity
Determining whether a chemical will cause
reversible or irreversible damage to the
human eye has traditionally been accom-
plished by using laboratory animals. The
test method assesses damage to three tissues
that differ in structure and function: the
cornea, the conjunctiva, and the iris. The
standard test method has been revised to
reduce the number of animals required to
as few as one animal. The test protocol has
also been refined to allow for termination
ofthe test whenever severe pain or distress
occurs. In vitro tests have been developed
that model one or two, but not all three
tissues. Test methods that use recon-
structed tissue equivalents or isolated eye
tissues are available that can and should be
used in tiered testing approaches. Further
progress in ocular toxicity test methods will
require additional research to better under-
stand the mechanisms involved in ocular
injury and recovery, and to identify end
points predictive ofpermanent injury.
DermalToxicity
Dermal toxicity can occur as dermal corro-
sion, dermal irritation, phototoxicity, or
allergic contact sensitization. Traditional test
methods for these end points use laboratory
animals. However, tiered testing approaches
can reduce, and in some instances eliminate,
the need for the animal test. For some prod-
ucts, decisions can be made to proceed to
human testing without prior animal testing,
but only after approval by an ethical review
committee. In vitro methods currently used
or under evaluation in tiered testing
approaches include cell cultures, reconsti-
tuted tissue equivalent cultures, and skin
explants. In some countries, in vitromethods
have been approved to assess the dermal cor-
rosion potential for some chemicals for
transportation purposes. In the area ofaller-
gic contact dermatitis, advances in the
understanding of cellular and molecular
mechanisms are expected to lead to the
development ofuseful in vitrotest methods.
AcuteSystemicToxicity
Acute systemic toxicity testing is conducted
to assess the potential for a chemical to
cause systemic toxicity or death following
an acute oral, dermal, or inhalation expo-
sure. This testing currently requires the use
oflaboratory animals. However, the origi-
nal LD50 test, which used a large number
ofanimals in each dose group, is no longer
required or necessary. New methods that
provide for the reduction and refinement
oflaboratory animal use are now approved
as international test guidelines and should
be used to meet acute toxicity testing
requirements. Testing for acute systemic
toxicity should be accomplished in a step-
wise, tiered testing approach that begins
with the collection and integration of
information on physical and chemical
properties, information from literature
reviews, and an analysis of structure-
activity relationships. In vitro cytotoxicity
determinations can aid in predicting acute
toxicity and should be considered in a
tiered testing approach.
Validation andPredictionModels
Extensive efforts have been made to
validate replacement tests for skin and eye
irritation during recent years. Experience
from these efforts has led to the recom-
mendation that algorithms, or prediction
models, be established as an integral part of
the test method to facilitate interpretation
ofthe data. Validation studies maydemon-
strate that a new test method is useful for
determining the toxicity of certain groups
or classes of chemicals, but not the entire
universe of chemicals. Validation studies
mayalso demonstrate that a new method is
useful for detecting toxicity, but not useful
for detecting lack of toxicity (high degree
of sensitivity, but poor specificity). The
converse is also a possible outcome ofvali-
dation studies (poor sensitivity, but high
specificity). As a test method is used and its
performance database enlarged, there is the
possibility that its usefulness for predicting
toxicity or nontoxicity maychange.
Reommendations
The following are recommendations from
the SGOMSEC workshop (2) relating to
the development and use of alternative
methods for acute toxicity:
* Continued support ofthe development
and validation ofalternative methods is
essential and is expected to lead to
continued improvement in the safety
evaluation ofchemicals.
* Research should be directed toward a
better understanding of the relevant
biology (especially human) of toxic
events and mechanisms.
* Better methods are needed to synthesize
information from batteries ofalternative
tests and to improve interpretation of
the integrated results.
* Users of alternative methods should
adopt the general scheme for toxicity
testing (2).
* Validated and accepted alternative
methods should be used immediately.
Implementation of methods providing
equivalent information should be prior-
itized according to the degree that they
use fewer animals or cause less stress.
* Given the expected rapid progress in the
development of new alternative meth-
ods, it is recommended that scientists,
regulators, potential users, and policy
makers establish and use continuing
education and information distribution
programs to stay currentwith progress.
Alternative Testing
Methodologiesfor
Organ Toxicity
The detection oforgan toxicity is a critical
component of toxicological testing. This
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toxicity is usually assessed in subchronic
repeat-dose testing using laboratory ani-
mals. However, in recent years there has
been substantial progress in the develop-
ment ofin vitro test methods that are help-
ful in assessing organ toxicity. Model
systems cover the full range of organiza-
tional structure, and include the use ofiso-
lated perfused whole organs, tissue slices,
isolated suspended cells, primary cells and
early subcultures, established cell lines,
subcellular fractions, and genetically engi-
neered cell systems. A significant advantage
of some of these systems is that they use
human tissues, which may provide data of
greater relevance for human toxicity. The
parallel use of both animal tissues and
human tissues can provide comparative
data helpful in interpreting the relevance of
animal dataforhuman toxicity.
LiverToxicity
The liver is both a major detoxification
organ and a major target organ for toxicity
for systemically absorbed chemicals. The
liver can metabolically activate chemicals to
forms that are hepatotoxic or toxic to other
organs and tissues. The liver can also meta-
bolically inactivate chemicals that might
otherwise appear toxic to other tissues in in
vitro test systems. In vitro liver preparations
can be used to obtain information on
chemical metabolism, enzyme induction
and inhibition, and drug-drug interactions.
The most useful in vitro liver preparations
are tissue slices and isolated hepatocytes.
Species differences are well documented in
liver-metabolizing enzymes and this often
creates uncertainties in extrapolating animal
test data to humans. Human and rodent
liver slices can be used to assess the compar-
ative metabolism of chemicals. This infor-
mation can then be helpful in interpreting
species differences in toxicity and in select-
ing the appropriate animal model. Liver
microsome preparations can be used for in
vitro systems to simulate hepatic metabolic
activation and inactivation of chemicals.
For example, microsome preparations have
been adapted for use in the Salmonella
mutagenicity assay and the Frog Embryo
Teratogenesis Assay in Xenopus develop-
mental toxicity assay. Specific human
cytochrome P450 enzymes produced in
genetically engineered cells are also now
available for use in in vitrosystems.
RenalToxicity
The kidney is especially susceptible to
injury from bloodborne toxicants and their
metabolites due to the high rate of renal
blood flow and the potential for concen-
tration in the kidney. Enzymes located in
renal epithelial cells may bioactivate drugs
and other xenobiotics to toxic forms.
Several in vitropreparations are available for
the study ofthe mechanistic and compara-
tive aspects ofrenal toxicity, including iso-
lated perfused kidneys, renal tissue slices,
tubular fragments, primary cell cultures,
and established renal epithelial cell lines.
Toxic mechanisms can be studied by assess-
ing various kidney-specific parameters such
as uptake, interaction with cellular target
sites, and cellular responses. In vitro
nephrotoxicity methods are being improved
to generate useful information regarding
toxic mechanisms, interspecies differences,
and in vitro-in vivoextrapolations.
Neurotoxicity
Neurotoxicity is commonly assessed using
a tiered testing approach that requires lab-
oratory animals at all levels. The first tier
consists of data collected during sub-
chronic rodent toxicity testing. The sec-
ond tier consists of detailed behavioral
observations, specific motor and sensory
function measurements, and neuropatho-
logic examinations. Third-tier studies are
aimed at further characterization ofneuro-
toxic effects and identification of possible
mechanisms ofaction. Several in vitro test
methods can be used in third-tier testing
to investigate neurotoxic mechanisms at
the cellular and molecular level. These
include organotypic explants, brain slices,
reaggregate cultures, primary cell prepara-
tions, and established cell lines. Coculture
systems also exist that can be used to
mimic the blood-brain barrier. These in
vitro systems are amenable to biochemical,
electrophysiological, and morphological
examinations. Furthermore, in vitro meth-
ods allow for study of alterations in gene
expression caused by toxicants. These in
vitro approaches can also be useful as
screening tools for particular situations or
classes ofcompounds.
Hemaotoxicity
Hematoxicants can act directly on circu-
lating blood cells or their precursor stem
cells in the bone marrow, or they can act
indirectly by inducing an immune response
against these cell types. One example ofan
in vitro test being used to study potential
toxicity to stem cells is the colony-forming
unit-granulocyte/macrophage assay. This
assay is being evaluated for its usefulness in
predicting the level of chemical exposure
that induces severe neutropenia.
Immunotoxicity
Immunotoxicity from chemicals may result
from heightened immune activity or
decreased immune function. Chemical-
induced immunosuppression is manifested
by the reduced ability to combat infectious
agents or tumors and has traditionally been
evaluated using a two-tiered in vivo
approach. Each tier consists of at least five
assays that depend on evaluation ofimmune
cells from chemically exposed mice. A recent
study (11) demonstrated that using only
three tests from each tier is sufficient to pre-
dict immunotoxicity, thus reducing the
number of animals required. Immuno-
toxicity due to heightened immune activity
is manifested by either hypersensitivity or
autoimmunity. Evaluation of chemicals for
hypersensitivity currently requires animal
testing, with the guinea pig as the traditional
model. Improved understanding of the
mechanisms ofhypersensitivity has resulted
in the development and validation of the
local lymph node assay in mice. This alterna-
tive assay requires less time, expense, and
animal distress than the traditional test.
Reproductive and
DevelopmentalToxicity
The potential reproductive toxicity of
chemicals is evaluated in multigenerational
studies using laboratory animals. The lack
of validated nonanimal alternatives is
attributable to the complexity ofreproduc-
tion. Reproductive toxicity must evaluate
effects on male and female fertility that
might occur from chemical exposure to the
fetus and during the entire postnatal period
through adulthood. In vitro fertilization
techniques can be used to assess viability of
sperm and oocytes from exposed animals.
The potential ofa chemical to cause devel-
opmental toxicity is evaluated in pregnant
laboratory animals. Numerous in vitro cul-
ture systems have been evaluated as screen-
ing tests for developmental toxicity. These
include established cell lines, primary cell
cultures, nonmammalian embryos, and
mammalian embryos or primordia.
Endocrine Disrupters
Environmental endocrine disrupters have
been defined as exogenous agents that inter-
fere with the normal physiological effects of
endogenous hormones. Endocrine dis-
rupters exert their effects by mimicking the
endogenous hormone or byinterferingwith
its production, release, transport, metabo-
lism, binding, action, or elimination.
Multiple organs and cells at numerous sites
may be affected. Therefore a battery of in
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vivo and in vitro assays may be needed to
adequately assess the endocrine-disrupting
potential ofchemicals. A number ofin vivo
and in vitro assays have been proposed,
including those that evaluate receptor bind-
ing and alterations in gene expression. The
effects on gene expression can be accurately
measured using transcriptional activation
assays in mammalian and yeast cells.
Competitive binding assays have been
developed for several nuclear receptors and
binding globulins.
Recommendations
The following are recommendations from
the SGOMSEC workshop (3) for the devel-
opment and use of alternative methods in
organ toxicity:
* The infrastructure for alternative toxicity
testing should be improved through the
following actions: a) establish mecha-
nisms to increase the availability, distri-
bution, and use of human tissues and
cells for alternative toxicology testing;
b) develop and make available relevant
reference compounds for toxicity assess-
ment in each organ system; c) organize
and make available via the internet
complete in vivo toxicology data,
including human data, that contain
dose, end points, and toxicokinetics
whenever available; and d) establish
mechanisms to assure that biological
material, reference chemicals, and data
are subject to international standards
for quality control and assurance.
* Biological end points for target organ
toxicity that can be reliably used in
developing alternative strategies should
be identified andvalidated.
* Alternative methodologies to predict tar-
get organ toxicityshould bedeveloped.
* Procedures to assure early standard-
ization of alternative tests should be
developed.
* The number ofin vitrotests usedfor tar-
get organ toxicity should be minimized
byusingthe mostpredictive ones.
* Alternative methodologies to detect tox-
icity due to multiple organ interactions
should be developed.
* Structure-activity relationships and
computational models should be given
a high priority for development and
validation as alternative approaches to
reduce animal testing.
* Coculture models involving bioactivat-
ing cells, tissues, and subcellular frac-
tions with other target cells in static
and perfused systems should be devel-
oped, standardized, andvalidated.
* Development of the battery of trans-
genic cells that express the range of
human cytochrome P450s should be
completed and used as an alternative to
animal-derived S9 microsomes in
assessments to predict human risk.
* The origin and suitability of cultured
cell lines to assess particular toxicants
should be carefully evaluated. For exam-
ple, tumor-derived cell lines should only
be used in alternative methods if they
are derived from tumors that are not
resistant to cytotoxic anticancer drugs.
Alternative Testing
Methodologies for
Ecotoxicology
Ecotoxicologic testing determines the
potential toxicity of chemicals to nonhu-
man organisms ranging from mammals to
invertebrates. In general, ecotoxicology is
concerned more with the health ofpopula-
tions and communities than with that of
individuals. Ecotoxicology studies use a
small number of species as surrogates for
all other nonhuman species of concern,
which often results in significant uncer-
tainty in species-to-species extrapolations.
Ecotoxicology assessments are especially
complex because of the need to consider
direct effects on organisms, as well as indi-
rect effects such as toxicity to critical food
sources. Exposure assessments for ecotoxi-
cology are also difficult and require consid-
eration offood chain bioaccumulation, and
distribution/fate ofchemicals in soil, water,
and air.
Biomarkers
Biomarkers are biological responses to
environment chemicals that can provide
measures of exposure and toxic effect.
These responses may include biochemical,
physiological, immunological, histological,
morphological, and behavioral changes.
Measurement of biomarkers can assess
whether a chemical has induced biological
effects that may lead to or are indicative of
adverse health effects. Control data and an
understanding of factors that cause varia-
tions in background values of biomarkers
are essential. Sensitive biomarkers indica-
tive of major biological functions such as
growth and reproduction are needed to
fully assess the impact of chemicals.
Biomarkers in sentinel species can serve as
early-warning indicators of environmental
effects of chemicals. An initial step in this
approach is to mechanistically link bio-
marker responses ofindividuals to changes
at population and communitylevels.
ObservationofCommunity Structure
Methods are available for directly assessing
disturbances at the community level. One
example is the River Invertebrate Predic-
tion and Classification System, which is
used to assess the biological quality of
rivers. This system generates site-specific
predictions of the invertebrate fauna of a
healthy community. This prediction is
then compared with the observed fauna of
the exposed community. A second example
is the Invertebrate Community Index,
which is used to assess invertebrate commu-
nity structure and function. Another exam-
ple is the Index of Biotic Integrity, which
measures the effects of contaminants on
aquatic communities. This index derives a
quantitative index of aquatic community
health from water characteristics and
fish populations.
AlternativeSystems
Model systems and approaches used for
ecotoxicology indude cultured cells, trans-
fected cell lines, microorganisms, fish
embryos, insects, QSAR, and nondestruc-
tive sampling from vertebrate species. Fish
hepatocyte cultures have been employed to
measure toxicity as evidenced by increases
in stress proteins, cytochrome P4501A1,
DNA adducts, and vitellogenin levels. A
luminescent bacterium,Vibriofischeri, that
responds to toxicants with a change in light
emission is being used as an environmental
toxicity screen. A 48-hr zebrafish embryo
assay has been used to detect developmen-
tal toxicity to aquatic species. Insects have
numerous advantages for toxicity studies
and have been used to assess reproductive
toxicity. Several standard mutagenicity
tests have been developed in the fruitfly
Drosophila melanogaster.
Useful information can also be obtained
from nondestructive sampling. Samples
such as blood, skin, eggs, and feces can be
used to measure biomarker responses to
toxicants. Behavioral effects can also be
observed in the field andthelaboratory.
Recommendtions
The following are recommendations from
the SGOMSECworkshop (4) for the devel-
opment and use of alternative methods
for ecotoxicology:
* Strategies and goals should be more
clearly defined when testing procedures
are undertaken.
* In the context of environmental risk
assessment, the objectives of the 3Rs
will be served by a) development and
improvement of assays to incorporate
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new techniques from biochemical/
molecular biology that relate to mecha-
nisms; b) further development of non-
destructive assays for vertebrates, and
assays for invertebrates; c) selection of
the most appropriate species, strains
and developmental stages in light of
new knowledge (but no additional ver-
tebrate species for basic testing); and
d) better integrated approaches incor-
porating biomarker assays, ecophysio-
logical concepts, and ecological end
points. Maximum success depends on a
flexible approach and exercising expert
judgment in interpretation.
* Testing protocols need to be realistic,
taking into account particular prob-
lems with mixtures and volatile or
insoluble chemicals.
Summary
Alternative methods that provide useful
information for human health and envi-
ronmental risk assessments are now avail-
able in all areas of toxicity testing. Some
methods can replace traditional methods,
whereas others are useful in tiered testing
approaches. Still other methods provide
mechanistic information that is helpful in
interpreting data from laboratory animal
models. These mechanistically based meth-
ods provide improved predictions oftoxic-
ity, and some provide savings in time and
cost. Alternative methods also reduce the
numbers ofanimals required for toxicolog-
ical assessments, and many incorporate
refined end points that are more humane.
Continued international cooperation will
facilitate future progress in the develop-
ment ofalternative toxicological test meth-
ods. These methods will provide for
worldwide improvements in human health
protection, environmental protection, and
animalwelfare.
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